Below are the most recent publications written about "Carcinoma in Situ" by people in Profiles.
-
Sangoi AR, Shahabi A, Hirsch MS, Kao CS, Deebajah M, Barletta JA, Paner GP, Smith SC, Grignon DJ, Comp?rat E, Amin MB, Maclean F, Shah RB, Iczkowski KA, Delprado W, Cheng L, Pan CC, McKenney JK, Ro JY, Khani F, Montironi R, Robinson BD, Al-Ahmadie H, Epstein JI, Trpkov K, Tretiakova M, Shen SS, Alanee S, Weight CJ, Akgul M, Williamson SR. Urothelial carcinoma in situ with "early papillary formation" vs "lateral spread/shoulder lesion" of prior high-grade noninvasive papillary urothelial carcinoma: A survey of pathologist and urologist interpretations. Am J Clin Pathol. 2025 04 19; 163(4):629-640.
-
Necchi A, Roumigui? M, Kamat AM, Shore ND, Boormans JL, Esen AA, Lebret T, Kandori S, Bajorin DF, Krieger LEM, Niglio SA, Uchio EM, Seo HK, de Wit R, Singer EA, Grivas P, Nishiyama H, Li H, Baranwal P, Van den Sigtenhorst-Fijlstra M, Kapadia E, Kulkarni GS. Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2024 06; 25(6):720-730.
-
Narayan VM, Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS, Lerner SP, Busby JE, Poch M, Crispen PL, Steinberg GD, Schuckman AK, Downs TM, Mashni J, Lane BR, Guzzo TJ, Bratslavsky G, Karsh LI, Woods ME, Brown G, Canter D, Luchey A, Lotan Y, Inman BA, Williams MB, Cookson MS, Chang SS, Sankin AI, O'Donnell MA, Sawutz D, Philipson R, Parker NR, Yla-Herttuala S, Rehm D, Jakobsen JS, Juul K, Dinney CPN. Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Gu?rin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial. J Urol. 2024 07; 212(1):74-86.
-
Hong MJ, Lum SS, Dupont E, Howard-McNatt M, Chiba A, Levine EA, Gass JS, Gallagher K, Fenton A, Murray M, Solomon NL, Ollila DW, Lazar M, Namm JP, Walters LL, Chagpar AB. Omission of Radiation in Conservative Treatment for Breast Cancer: Opportunity for De-escalation of Care. J Surg Res. 2022 11; 279:393-397.
-
Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS, Lerner SP, Busby JE, Poch M, Crispen PL, Steinberg GD, Schuckman AK, Downs TM, Svatek RS, Mashni J, Lane BR, Guzzo TJ, Bratslavsky G, Karsh LI, Woods ME, Brown G, Canter D, Luchey A, Lotan Y, Krupski T, Inman BA, Williams MB, Cookson MS, Keegan KA, Andriole GL, Sankin AI, Boyd A, O'Donnell MA, Sawutz D, Philipson R, Coll R, Narayan VM, Treasure FP, Yla-Herttuala S, Parker NR, Dinney CPN. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2021 01; 22(1):107-117.
-
Shields CL, Kim M, Lally SE, Ch?vez-Barrios P, Shields JA. Eye cancer in a young male with a vaping history. Indian J Ophthalmol. 2020 Aug; 68(8):1699-1701.
-
Goodman CR, DeNittis A. Photon irradiation using a water bath technique for treatment of confluent carcinoma in situ of the hand, digits, and nail bed: a case report. J Med Case Rep. 2017 Mar 30; 11(1):86.
-
Donin NM, Chamie K, Lenis AT, Pantuck AJ, Reddy M, Kivlin D, Holldack J, Pozzi R, Hakim G, Karsh LI, Lamm DL, Belkoff LH, Belldegrun AS, Holden S, Shore N. A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer. Urol Oncol. 2017 02; 35(2):39.e1-39.e7.
-
Redrow GP, Guo CC, Brausi MA, Coleman JA, Fernandez MI, Kassouf W, Keeley FX, Margulis V, Raman JD, Roupret M, Shariat SF, Spiess PE, Thalmann GN, Matin SF. Upper Urinary Tract Carcinoma In Situ: Current Knowledge, Future Direction. J Urol. 2017 02; 197(2):287-295.
-
Scott RB, Dolkar T, Vidhun R, Osler T, Staradub VL. Does Initial Imaging Modality Affect Breast Biopsy Upgrade Rates? A Single Institution Review. Conn Med. 2016 Jun-Jul; 80(6):335-40.